About Acesion Pharma
Acesion Pharma is a company based in Copenhagen (Denmark) founded in 2011 by Morten Grunnet.. Acesion Pharma has raised $68.42 million across 10 funding rounds from investors including European Union, Canaan and Innovationsfonden. The company has 12 employees as of November 30, 2024. Acesion Pharma has completed 1 acquisition, including Coinify. Acesion Pharma offers products and services including AP30663 and AP31969. Acesion Pharma operates in a competitive market with competitors including Thryv Therapeutics, MITEM Pharma, Inomagen, Blue Ash Therapeutics and Rhythm Therapeutics, among others.
- Headquarter Copenhagen, Denmark
- Employees 12 as on 30 Nov, 2024
- Founders Morten Grunnet
- Stage Minicorn
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Acesion Pharma Aps
-
Annual Revenue
-
Net Profit
$-6.18 M (USD)-64as on Dec 31, 2019
-
EBITDA
$-7 M (USD)-53as on Dec 31, 2019
-
Total Equity Funding
$68.42 M (USD)
in 10 rounds
-
Latest Funding Round
$47 M (USD), Series B
Sep 26, 2023
-
Investors
European Union
& 8 more
-
Employee Count
12
as on Nov 30, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Acesion Pharma
Acesion Pharma offers a comprehensive portfolio of products and services, including AP30663 and AP31969. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Inhibitor targeting SK ion channel for atrial fibrillation treatment.
Novel therapy for managing atrial fibrillation symptoms effectively.
Unlock access to complete
Leadership Team
2 people
Finance and Accounting
1 people
COO Team
1 people
Operations Team
1 people
Unlock access to complete
Funding Insights of Acesion Pharma
Acesion Pharma has successfully raised a total of $68.42M across 10 strategic funding rounds. The most recent funding activity was a Series B round of $47 million completed in September 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 10
- Last Round Series B — $47.0M
-
First Round
First Round
(01 Jan 2011)
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2023 | Amount | Series B - Acesion Pharma | Valuation | Canaan , Alpha Wave Global | |
| Sep, 2020 | Amount | Series B - Acesion Pharma | Valuation |
investors |
|
| May, 2019 | Amount | Series B - Acesion Pharma | Valuation | FC Capital |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Acesion Pharma
Acesion Pharma has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include European Union, Canaan and Innovationsfonden. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Canaan is recognized as an early-stage venture capital firm.
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on growth-stage companies
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Acesion Pharma
Acesion Pharma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Coinify. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Crypto-based payment solution for consumers and businesses
|
2014 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Acesion Pharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Acesion Pharma Comparisons
Competitors of Acesion Pharma
Acesion Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Thryv Therapeutics, MITEM Pharma, Inomagen, Blue Ash Therapeutics and Rhythm Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Provider of therapy services for rare diseases
|
|
| domain | founded_year | HQ Location |
Targeted therapies for multiple diseases are developed.
|
|
| domain | founded_year | HQ Location |
Gene therapy for cardiovascular diseases is developed using electroporation.
|
|
| domain | founded_year | HQ Location |
Develops innovative drugs targeted at treating cardiovascular disorders.
|
|
| domain | founded_year | HQ Location |
Gene therapy for atrial fibrillation is developed in preclinical stage.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Acesion Pharma
Frequently Asked Questions about Acesion Pharma
When was Acesion Pharma founded?
Acesion Pharma was founded in 2011.
Where is Acesion Pharma located?
Acesion Pharma is headquartered in Copenhagen, Denmark.
Who is the current CEO of Acesion Pharma?
Frans Wuite is the current CEO of Acesion Pharma.
Is Acesion Pharma a funded company?
Acesion Pharma is a funded company, having raised a total of $68.42M across 10 funding rounds to date.
How many employees does Acesion Pharma have?
As of Nov 30, 2024, the latest employee count at Acesion Pharma is 12.
What does Acesion Pharma do?
Acesion Pharma was founded in 2011 in Copenhagen, Denmark, as a biotech firm focused on cardiac arrhythmia treatments. Atrial fibrillation, the most common arrhythmia, is addressed through drugs targeting SK ion channels to regulate heart rhythm. The lead candidate, AP30663, has completed phase 1 clinical trials. Operations emphasize drug development in the cardiovascular sector, with activities based in Europe.
Who are the top competitors of Acesion Pharma?
Acesion Pharma's top competitors include Thryv Therapeutics, MITEM Pharma and Inomagen.
What products or services does Acesion Pharma offer?
Acesion Pharma offers AP30663 and AP31969.
How many acquisitions has Acesion Pharma made?
Acesion Pharma has made 1 acquisition, including Coinify.
Who are Acesion Pharma's investors?
Acesion Pharma has 9 investors. Key investors include European Union, Canaan, Innovationsfonden, Alpha Wave Global, and Global BioAccess.
What is Acesion Pharma's valuation?
The valuation of Acesion Pharma is $28.49M as of Sep 2020.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.